Syros Announces Appointment of Alice T. Shaw to its Board of …
Syros’ lead drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with acute myeloid leukemia, and SY-1365, a …
Syros Pharmaceuticals Presents Data Demonstrating Significant …
Syros in-licensed SY-1425, which is approved in Japan as tamibarotene to treat acute promyelocytic leukemia, to develop and commercialize SY-1425 in North America and Europe …
Except where the context otherwise requires, references to “Syros Pharmaceuticals,” “the Company,” “we,” “us,” “our” and similar terms refer to Syros Pharmaceuticals, Inc.
SYROS PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 45-3772460 (I.R.S. …
Re: Syros Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-239141) Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the …
ir.syros.com
%PDF-1.4 1 0 obj /Title (?8-K) /Creator (?wkhtmltopdf 0.12.5) /Producer (?Qt 4.8.7) /CreationDate (D:20210526083215-04'00') >> endobj 3 0 obj /Type /ExtGState /SA true /SM 0.02 /c